文献速递乳腺癌放疗头颈部肿瘤放疗

乳腺癌锁骨上区放疗后甲状腺功能减退的NTCP模型

NTCP model for hypothyroidism after supraclavicular-directed radiation therapy for breast cancer.
PubMed 文献 · Radiother Oncol · 2020-09-11

多因素分析显示随访时间较长和甲状腺接受<20 Gy的体积(CV20Gy[cc])较大是显著预后因素,NTCP模型提示CV20Gy≥8.5 cc与HT风险<15%相关。

要点

  • 锁骨上区放疗后HT发生率为19.3%,中位随访25个月。
  • 甲状腺CV20Gy[cc]较大和随访时间较长是HT的显著预后因素。
  • NTCP模型提示CV20Gy≥8.5 cc与HT风险<15%相关。

核心结论

  • NTCP模型提示甲状腺接受<20 Gy的体积大于8.5 cc可能是降低乳腺癌锁骨上区放疗后HT风险的推荐剂量学指标。

研究设计与样本

  • 回顾性分析2007至2019年间192例接受锁骨上区定向放疗且符合纳入标准的乳腺癌患者。
  • 分析个体剂量体积直方图,采用多因素逻辑回归评估HT的临床和治疗因素,并建立和验证NTCP模型。

主要发现

  • 多因素分析显示随访时间较长(p=0.015)和甲状腺接受<20 Gy的体积(CV20Gy[cc];p=0.045)是显著预后因素(p=0.039)。
  • IMRT与HT风险增加无关(p=0.28),尽管IMRT组CV20Gy[cc]较低(p=0.0002)。
  • NTCP模型显示CV20Gy[cc]≥8.5 cc与HT风险<15%相关;对于较小甲状腺,平均剂量和甲状腺体积可预测HT风险。
  • 模型验证显示本研究模型与其他已发表模型性能相当(AUC 0.69-0.72)。

关键数值与推荐

  • 甲状腺CV20Gy[cc]≥8.5 cc与HT风险<15%相关。

临床怎么用

  • 在接受锁骨上区定向放疗的乳腺癌患者中,可考虑将甲状腺CV20Gy[cc]≥8.5 cc作为剂量学参考以降低HT风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Hypothyroidism (HT) is a well-known complication of radiation (RT) that includes supraclavicular (SCV) fields. We analyzed breast cancer patients who received SCV-directed RT to evaluate predictors of HT and developed the first normal tissue complication probability (NTCP) model for HT specific to breast cancer patients. MATERIALS AND METHODS: 192 breast cancer patients received SCV-directed RT between 2007 and 2019 and met inclusion criteria. Individual dose-volume histograms were analyzed to determine thyroid volume within and outside specific isodose lines as well as minimum, mean, and maximum doses. Multivariable logistic regression was performed to assess potential clinical and treatment factors for the development of hypothyroidism. An NTCP model was created, and model validation was performed. RESULTS: Thirty-seven patients (19.3%) developed HT following SCV-directed RT at a median 25 months (range: 2-83 months). Multivariable analysis revealed longer length of follow-up (p = 0.015) and larger thyroid volume receiving less than 20 Gy (CV20Gy[cc]; p = 0.045) were significant prognostic factors (p = 0.039). IMRT was not associated with an increased risk of hypothyroidism (p = 0.28) despite lower CV20Gy[cc] (p = 0.0002). On NTCP modeling, CV20Gy[cc] ≥ 8.5 cc was associated with a risk of HT < 15%. For smaller thyroids, mean dose and thyroid volume were found to be predictive of HT risk. Model validation demonstrated comparable performances between our model and other published models (AUC 0.69-0.72). CONCLUSION: NTCP modeling within our patient cohort suggested that greater than 8.5 cc thyroid volume receiving less than 20 Gy may be a recommended dosimetric guideline to minimize HT risk in breast cancer patients receiving SCV-directed RT.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Huang H, Roberson J, Hou W, et al. NTCP model for hypothyroidism after supraclavicular-directed radiation therapy for breast cancer. Radiother Oncol. 2020. PMID: 32926911. doi:10.1016/j.radonc.2020.09.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。